PEOPLE - OrbusNeich makes appointments:
This article was originally published in Clinica
Executive Summary
Hong Kong-based manufacturer of the Genous bio-engineered R stent OrbusNeich has appointed cardiology industry specialists Massimo Chiesa and Per Arne Winberg as directors within the sales and marketing team. Mr Chiesa (formerly with EuroCor International, Volcano Therapeutics, Jomed and SCIMed) will cover western Europe, the Middle East and Latin America out of Milan; and Mr Winberg (formerly with Abbott Vascular, Jomed and Cordis) northern and eastern Europe out of Copenhagen. The appointments come at a time when OrbusNeich is seeing increased demand in Europe for its product, in light of certain physicians' concerns with DESs.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.